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Pivotal and Continued Access Trials.
METHODS Patients in the CoreValve US Pivotal and Continued Access
trials were examined with respect to whether they underwent balloon
dilation of the CoreValve frame after valve implantation. Clinical,
anatomic, procedural and outcome data were analyzed. Best practice
guidelines in these trials recommended pre-dilation of the native
valve prior to CoreValve deployment, with BPD of the CoreValve
frame reserved for treatment of suboptimal intraprocedural stent
valve function.
RESULTS Procedural BPD was performed in 782 of 3532 patients (22%).
Male sex, larger aortic annular diameters, greater baseline aortic gra-
dients and aortic regurgitation (AR) were seen in the patients who
underwent balloon post-dilation (Table). The incidence of balloon pre-
dilation of the native valve and the CoreValve implant depth were
similar between those who did and did not undergo BPD. BPD was
performed less frequently with the 26 mm valve (17.9%) as compared to
the 31 mm valve (38.0%). The most common indication for BPD was 
moderate AR following CoreValve deployment which accounted for
58.1% of BPD patients. BPD was effective in acutely reducing AR in the
majority of these patients, with 78.0% with moderate AR having mild
or no AR after BPD. In-hospital major adverse cardiovascular and ce-
rebrovascular event rates were similar between no BPD (7.5%) and BPD
(9.3%) groups; p¼0.10. One case of valve migration and 3 cases of fatal
cardiac perforation occurred following BPD.
Table. Baseline CharacteristicsNo BPD
N [ 2750BPD
N [ 782 P ValueAge (years) 83.3  7.7 83.6  7.9 0.30
Female sex 49.3 % 37.5 % <0.0001Mean annular diameter
(mm)24.4  2.2 25.2  2.2 <0.0001Annular sizing ratio
<10%12.2% 24.0% <0.0001Mean aortic gradient
(mmHg)41.3  15.7 44.8  16.5 <0.0001Baseline AR 
moderate13.9% 21.5% <0.0001CONCLUSIONS Balloon post-dilation of the CoreValve bioprosthesis
was performed in 22% of patients in the CoreValve US Trials, most
commonly in patients with larger valve annulus measurements and
those with more severe baseline aortic valve dysfunction. The most
frequent indication for balloon post dilation was moderate or severe
aortic regurgitation. Balloon post-dilation was effective in acutely
improving valve performance and reducing aortic valve regurgitation
in the majority of these patients.
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BACKGROUND The long-term performance of SAPIEN transcatheter
aortic valve replacement (TAVR) is not known. Therefore, we exam-
ined the hemodynamic proﬁle of SAPIEN TAVR over 5 years of
follow-up and compared these results with surgical bioprosthetic
aortic valve replacement (SAVR).METHODS All patients receiving SAPIEN TAVR or SAVR with ﬁrst
post implant (FPI) and 5-year echoes were analyzed by an indepen-
dent echo core lab for: aortic valve (AV) peak velocity, AV mean
gradient, AV area (AVA), AVA indexed for body surface area, pre-stent
velocity in the left ventricular outﬂow tract (LVOT), in-stent (pre-
leaﬂet) velocity, time velocity integrals (TVI), Doppler velocity index
(DVI) and total, transvalvular and paravalvular aortic regurgitation
(AR). FPI and 5-year data were compared using paired t-test and
McNemar’s analyses.
RESULTS 91 SAPIEN TAVR and 48 SAVR patients had AV hemody-
namic assessments on FPI and 5 year echoes (Figure). AVA and AVA
index were unchanged 5 years after SAPIEN TAVR (p¼0.59 and
p¼0.72). AV mean gradient also did not change: 11.85.6 mmHg at
FPI to 10.96.1mmHg at 5 years, p¼0.21. In contrast, peak LVOT and
AV velocities decreased (both p¼0.02), as did in-stent velocity,
p¼0.01. Correspondingly, TAVR DVI using LVOT TVI or in-stent TVI
were unchanged, p¼0.16 and p¼0.09, respectively. There was no
signiﬁcant change in overall total AR (p¼0.32), paravalvular AR
(p¼0.11) or transvalvular AR (p¼0.71) over time among TAVR
patients. The results of longitudinal hemodynamic evaluation of
SAVR patients were similar to that seen in patients receiving
SAPIEN TAVR.
CONCLUSIONS Independent longitudinal assessment of the SAPIEN
TAVR shows that valve hemodynamics are stable 5 years after im-
plantation and similar to those for SAVR. These results indicate good
long term durability and support the use of TAVR in high-risk
patients.
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BACKGROUND Self-expanding transcatheter aortic valve replace-
ment (TAVR) is superior to medical therapy for pts with severe native
